RESEARKA

Within the corpus, notable tensions emerge between studies reporting positive contextual effects and those finding null results. This trial, registered as NCT01785329, evaluated the relative pharmacokinetics, pharmacodynamics, and safety of the antibody in a controlled clinical setting. The study design focused on healthy adults to establish baseline kinetic parameters without the confounding effects of comorbidities or concomitant lipid-lowering therapies. The integration of evidence from these healthy-subject kinetics studies and high-risk patient efficacy trials provides a comprehensive view of alirocumab's dose-response relationship.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023